Recent advances in systemic treatments for ovarian cancer

被引:9
|
作者
Banerjee, Susana [1 ]
Gore, Martin [1 ]
机构
[1] Royal Marsden NHS Fdn Trust, Gynaecol Unit, London, England
来源
CANCER IMAGING | 2012年 / 12卷 / 02期
关键词
Ovarian cancer; chemotherapy; targeted therapy; bevacizumab; PARP inhibitors; PHASE-III TRIAL; RECURRENT EPITHELIAL OVARIAN; PLATINUM-BASED CHEMOTHERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; PLUS CARBOPLATIN; RANDOMIZED-TRIAL; INTRAPERITONEAL CISPLATIN; PRIMARY PERITONEAL; INTERGROUP TRIAL; STAGE-III;
D O I
10.1102/1470-7330.2012.9002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer remains the leading cause of death from gynaecological cancer. Advances in surgical and chemotherapeutic strategies have led to improvements in outcome. However, the majority of women present with advanced disease with little prospect for cure. In this article, we summarize the systemic management and ovarian cancer and raise a number of important issues: namely the timing of systemic therapy in relation to surgery, the selection of patients who do not require systemic therapy and the development of novel agents.
引用
收藏
页码:305 / 309
页数:5
相关论文
共 50 条
  • [1] Advances in Epithelial Ovarian Cancer Therapy
    Kroep, J. R.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (25) : 3735 - 3740
  • [2] Biomarkers for Systemic Therapy in Ovarian Cancer
    Penzvalto, Zsofia
    Surowiak, Pawel
    Gyorffy, Balazs
    CURRENT CANCER DRUG TARGETS, 2014, 14 (03) : 259 - 273
  • [3] Considerations Regarding the Administration of Systemic Therapy for Elderly Patients With Ovarian Cancer
    Tew, William P.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (01) : 1 - 11
  • [4] Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer
    Markman, Maurie
    GYNECOLOGIC ONCOLOGY, 2013, 131 (01) : 241 - 245
  • [5] Recent advances in understanding the immune microenvironment in ovarian cancer
    Chen, Jinxin
    Yang, Lu
    Ma, Yiming
    Zhang, Ye
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [6] Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
    Rose, Peter G.
    CANCER DRUG RESISTANCE, 2022, 5 (02) : 415 - 423
  • [7] New Advances in Ovarian Cancer Ovarian Cancer Care: It's Time for "Personalized" Approaches
    Liu, Joyce
    Matulonis, Ursula A.
    ONCOLOGY-NEW YORK, 2010, 24 (08): : 721 - 728
  • [8] Ovarian Cancer: Advances in First-Line Treatment Strategies with a Particular Focus on Anti-Angiogenic Agents
    Collinson, Fiona J.
    Seligmann, Jenny
    Perren, Timothy J.
    CURRENT ONCOLOGY REPORTS, 2012, 14 (06) : 509 - 518
  • [9] First line chemotherapy of advanced epithelial ovarian cancer
    Lhomme, C.
    Even, C.
    Morice, P.
    Balleyguier, C.
    Petrella, M. C.
    Gouy, S.
    Uzan, C.
    Duvillard, P.
    Pautier, P.
    BULLETIN DU CANCER, 2009, 96 (12) : 1207 - 1213
  • [10] Recent advances in drug delivery strategies for treatment of ovarian cancer
    Zahedi, Payam
    Yoganathan, Roshan
    Piquette-Miller, Micheline
    Allen, Christine
    EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (05) : 567 - 583